In vitro studies indicated that MCL1-specific inhibitor S63845 and venetoclax could synergistically suppress T-ALL cells, but the two drugs had no independent killing effect on T-ALL cells, which might be due to the high expression of MCL1 and BCL2 in T-ALL cells [62]. This evidence concerns the gene MCL1 and acute lymphoblastic leukemia.